Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients

다국어 초록 (Multilingual Abstract)

Purpose: Cinacalcet is effective for treating refractory secondary hyperparathyroidism (SHPT), but little is known about the response rates and clinical factors influencing the response. Materials and Methods: A prospective, single-arm, multi-center study was performed for 24 weeks. Cinacalcet was administered to patients with intact parathyroid hormone (iPTH) level greater than 300 pg/mL. Cinacalcet was started at a dose of 25 mg daily and titrated until 100 mg to achieve a serum iPTH level <300 pg/mL (primary end point). Early response to cinacalcet was defined as a decrease of iPTH more than 50% within one month. Results: Fifty-seven patients were examined. Based on the magnitude of iPTH decrease, patients were divided into responder (n=47, 82.5%) and non-responder (n=10, 17.5%) groups. Among the responders, 38 achieved the primary end point, whereas 9 patients showed a reduction in serum iPTH of 30% or more, but did not reach the primary end point. Compared to non-responders, responders were significantly older (p=0.026), female (p=0.041), and diabetics (p<0.001). Additionally,early response was observed more frequently in the responders (30/47, 63.8%), of whom the majority (27/30, 90.0%) achieved the primary end point. Multivariate analysis showed that lower baseline iPTH levels [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.93-0.99], the presence of diabetes (OR 46.45, CI 1.92-1125.6) and early response (OR 21.54, CI 2.94-157.7) were significant clinical factors affecting achievement of iPTH target. Conclusion: Cinacalcet was effective in most hemodialysis patients with refractory SHPT. The presence of an early response was closely associated with the achievement of target levels of iPTH.

참고문헌 (Reference)

1 Drüeke TB, "Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives" 4 : 234-241, 2009

2 Chang W, "The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development" 1 : 2008

3 Shoback DM, "The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism" 88 : 5644-5649, 2003

4 Pei Y, "Renal osteodystrophy in diabetic patients" 44 : 159-164, 1993

5 Vincenti F, "Parathyroid and bone response of the diabetic patient to uremia" 25 : 677-682, 1984

6 Yamamoto M, "Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism" 16 : 292-299, 2012

7 Cozzolino M, "New insights into the role of calcium-sensing receptor activation" 24 (24): S38-S41, 2011

8 Tentori F, "Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)" 52 : 519-530, 2008

9 Young EW, "Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)" 44 (44): 34-38, 2004

10 Moe SM, "Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl" 20 : 2186-2193, 2005

11 Kalantar-Zadeh K, "Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals" S10-S21, 2010

12 National Kidney Foundation, "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease" 42 (42): S1-S201, 2003

13 Battistella M, "Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease" 76 : 99-103, 2011

14 Wald R, "Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network" 49 : 257-266, 2007

15 Cunningham J, "Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism" 68 : 1793-1800, 2005

16 Kruse AE, "Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism" 22 : 2362-2365, 2007

17 Lucchi L, "Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience" 35 : 1186-1193, 2011

18 Suzuki H, "Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, improve arterial stiffness in patients on continuous ambulatory peritoneal dialysis?" 27 : 134-139, 2011

19 Akizawa T, "Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns" 6 : 2280-2288, 2011

20 Vincenti F, "Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis" 245 : 930-933, 1981

21 Frazão JM, "Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity" 76 : 233-243, 2011

22 Block GA, "Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients" 78 : 578-589, 2010

23 Block GA, "Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis" 350 : 1516-1525, 2004

24 Komaba H, "Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism" 5 : 2305-2314, 2010

25 Lindberg JS, "Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study" 16 : 800-807, 2005

26 Dvorak MM, "Ca2+ as an extracellular signal in bone" 35 : 249-255, 2004

27 Segura Torres P, "Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet" 30 : 443-451, 2010

28 Moe SM, "Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl" 67 : 760-771, 2005

29 Goodman WG, "A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism" 58 : 436-445, 2000